King's College London

Research portal

Dual antiplatelet therapy in coronary artery disease: Comparison between ACC/AHA 2016 and ESC 2017 guidelines

Research output: Contribution to journalReview article

Standard

Dual antiplatelet therapy in coronary artery disease : Comparison between ACC/AHA 2016 and ESC 2017 guidelines. / Floyd, Christopher N.

In: European Cardiology Review, Vol. 15, e08, 01.01.2020.

Research output: Contribution to journalReview article

Harvard

Floyd, CN 2020, 'Dual antiplatelet therapy in coronary artery disease: Comparison between ACC/AHA 2016 and ESC 2017 guidelines', European Cardiology Review, vol. 15, e08. https://doi.org/10.15420/ecr.2019.09

APA

Floyd, C. N. (2020). Dual antiplatelet therapy in coronary artery disease: Comparison between ACC/AHA 2016 and ESC 2017 guidelines. European Cardiology Review, 15, [e08]. https://doi.org/10.15420/ecr.2019.09

Vancouver

Floyd CN. Dual antiplatelet therapy in coronary artery disease: Comparison between ACC/AHA 2016 and ESC 2017 guidelines. European Cardiology Review. 2020 Jan 1;15. e08. https://doi.org/10.15420/ecr.2019.09

Author

Floyd, Christopher N. / Dual antiplatelet therapy in coronary artery disease : Comparison between ACC/AHA 2016 and ESC 2017 guidelines. In: European Cardiology Review. 2020 ; Vol. 15.

Bibtex Download

@article{a97ee8bf807047ecab9a2ad76a815d2c,
title = "Dual antiplatelet therapy in coronary artery disease: Comparison between ACC/AHA 2016 and ESC 2017 guidelines",
abstract = "Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease (CAD) but there remains uncertainty as to the optimal approach for balancing an individual{\textquoteright}s risk of atherothrombotic events versus their risk of bleeding complications. A myriad of clinical trials have investigated how factors such as antiplatelet selection or duration of treatment can affect outcomes in both stable CAD and acute coronary syndromes. To aid clinicians in the challenge of applying trial findings to the circumstances of individual patients, the American College of Cardiology/American Heart Association and European Society of Cardiology have released focused updates on prescribing DAPT in CAD. While the two guidelines agree on many issues, there are some differences in the recommendations. This article highlights those differences and provides comment on their aetiology.",
keywords = "Acute coronary syndrome, Antiplatelet, Bleeding, Guidelines, Stent, Thrombosis",
author = "Floyd, {Christopher N.}",
year = "2020",
month = jan,
day = "1",
doi = "10.15420/ecr.2019.09",
language = "English",
volume = "15",
journal = "European Cardiology",
issn = "1758-3756",
publisher = "Radcliffe Publishing Ltd.",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Dual antiplatelet therapy in coronary artery disease

T2 - Comparison between ACC/AHA 2016 and ESC 2017 guidelines

AU - Floyd, Christopher N.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease (CAD) but there remains uncertainty as to the optimal approach for balancing an individual’s risk of atherothrombotic events versus their risk of bleeding complications. A myriad of clinical trials have investigated how factors such as antiplatelet selection or duration of treatment can affect outcomes in both stable CAD and acute coronary syndromes. To aid clinicians in the challenge of applying trial findings to the circumstances of individual patients, the American College of Cardiology/American Heart Association and European Society of Cardiology have released focused updates on prescribing DAPT in CAD. While the two guidelines agree on many issues, there are some differences in the recommendations. This article highlights those differences and provides comment on their aetiology.

AB - Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease (CAD) but there remains uncertainty as to the optimal approach for balancing an individual’s risk of atherothrombotic events versus their risk of bleeding complications. A myriad of clinical trials have investigated how factors such as antiplatelet selection or duration of treatment can affect outcomes in both stable CAD and acute coronary syndromes. To aid clinicians in the challenge of applying trial findings to the circumstances of individual patients, the American College of Cardiology/American Heart Association and European Society of Cardiology have released focused updates on prescribing DAPT in CAD. While the two guidelines agree on many issues, there are some differences in the recommendations. This article highlights those differences and provides comment on their aetiology.

KW - Acute coronary syndrome

KW - Antiplatelet

KW - Bleeding

KW - Guidelines

KW - Stent

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85083019270&partnerID=8YFLogxK

U2 - 10.15420/ecr.2019.09

DO - 10.15420/ecr.2019.09

M3 - Review article

AN - SCOPUS:85083019270

VL - 15

JO - European Cardiology

JF - European Cardiology

SN - 1758-3756

M1 - e08

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454